Stereotaxis, Inc. — Form 8-K
Filed July 9, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
Stereotaxis completed its acquisition of Robocath, a France-based developer of robotic solutions for interventional cardiology and neurointerventions, as of July 9, 2026. The filing does not disclose the purchase price, share count exchanged, or other financial terms. Robocath's R-One robotic platform has CE and NMPA certifications and is currently deployed in Europe and China; the combined entity aims to expand robotic offerings across electrophysiology, interventional cardiology, and neurointerventions.
Why this rating
Material M&A for $150M company; adds complementary platform, regulatory approvals, and installed base. Lack of disclosed price limits precision but strategic fit and technology expansion suggest meaningful near-term upside potential.
See more from July 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.